IPO-38 Antibody [IPO-38]

Flow Cytometry: 0.5-1 ug/million cells in 0.1ml

Immunofluorescence: 0.5-1 ug/ml

Immunohistochemistry (FFPE): 0.5-1 ug/ml for 30 min at RT (1)

Prediluted format: incubate for 30 min at RT (2)

Optimal dilution of the IPO-38 antibody should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Recognizes a protein of 14-16kDa, which is a novel nuclear antigen of proliferating cells. IPO38 antigen is present in the nuclei of proliferating cells such as Hodgkin s disease and non-Hodgkin s lymphomas, different forms of leukemias, breast and colorectal carcinomas, and PHA-stimulated lymphocytes. It is not expressed in the cells of non-stimulated lymphocytes and granulocytes. IPO38 may be a useful marker of cell proliferation during monitoring of tumor progression.

PBS with 0.1 mg/ml BSA and 0.05% sodium azide

0.2 mg/mL

Unconjugated

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.

Spleen cells from a patient with hairy cell leukemia were used as the immunogen for the IPO-38 antibody.

Liquid

PEG precipitation

Cancer

Not Known

Optimal dilutions for each application to be determined by the researcher